Cannabis Use and Outcomes in Black and White Patients With Cancer
Launched by STATE UNIVERSITY OF NEW YORK AT BUFFALO · Sep 7, 2023
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how Black and White patients with solid tumor cancers use cannabis, opioids, and tobacco to manage their pain and symptoms. Researchers want to understand the differences in usage and outcomes between these two groups of patients. To gather information, they will use a smartphone app and surveys where participants can report their experiences and symptoms. This study aims to improve healthcare practices and guidelines for cancer patients who are often underrepresented in research.
To be eligible for this study, participants must be 21 years or older, identify as Black or White, and have been diagnosed with a solid tumor cancer within the last three years. They should also be using cannabis at least once a week or have not used cannabis for the past three months. Additionally, participants need to be experiencing pain but should not spend more than half their day in bed or a chair. Those who are pregnant or planning to become pregnant in the next year cannot participate, and the study is open to all genders. If you join the study, you'll be asked to share your experiences regarding pain management and how cannabis and other substances affect you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 21 years or older
- • Black or white race
- • Solid tumor cancer within 3 years of enrollment
- • Cannabis use of at least once a week or non cannabis use for 3 months
- • experience pain but spend less than 50% in bed or chair
- • Prescribed or take opioid for at least 30 days for pain
- • Not pregnant or planning to become pregnant in the next 12 months
- • English speaking
- Exclusion Criteria:
- • Lymphoma, leukemia, and melanoma
- • CBD only use
- • Synthetic cannabis use in past 3 months = Prescribed Medically-prescribed synthetic cannabis (e.g., dronabinol \[Marinol, Syndros\], Epidiolex)
- • race other than Black or White
About State University Of New York At Buffalo
The State University of New York at Buffalo (SUNY Buffalo) is a prominent research institution dedicated to advancing healthcare through innovative clinical trials and studies. Renowned for its commitment to academic excellence and interdisciplinary collaboration, the university leverages its extensive resources and expertise to explore novel therapeutic approaches and enhance patient outcomes. SUNY Buffalo's clinical trials encompass a wide range of medical disciplines, driven by a mission to translate research discoveries into practical applications that benefit diverse populations. With a focus on ethical standards and rigorous methodologies, the university fosters an environment that supports cutting-edge research while prioritizing participant safety and well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Buffalo, New York, United States
Buffalo, New York, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Salimah Meghani, PhD
Principal Investigator
University of Pennsylvania
Brooke Worster, MD
Principal Investigator
Thomas Jefferson University
Rebecca L Ashare, PhD
Principal Investigator
University at Buffalo
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported